← Russell 3000 cross-section

BEAM Beam Therapeutics Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$3.1bn
Revenue TTM
$156m
Net income TTM
$-85m
Free cash flow
$-373m
Composite score
48.9
Sector rank
#1372

Valuation

P / E
EV / EBITDA
EV / sales
13.3
FCF yield
-11.93%
Earnings yield vs 10-yr
-7.46pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-54.8%
EBITDA margin
-228.0%
ROE
-8.0%
ROIC
-2,558.9%
Revenue growth
158.9%

Insider activity, last 90 days

Net open-market
$-12.23m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

A pancellular distribution of HbF, reflecting expression across most of the circulating red blood cells, was observed, with mean per-cell HbF levels maintained above the sickling threshold throughout follow-up. To date, we have financed our operations primarily through the sales of our redeemable convertible preferred stock, proceeds from offerings of our common stock, payments received under collaboration and license agreements, and our credit facility with Sixth Street Lending Partners, or the Credit Facility. We are a clinical-stage company, and our programs are at a preclinical or clinical stage of development. …Beam Therapeutics Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →